# H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

> **NCT05167643** · NA · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Advanced HR+ HER2 Negative Breast Carcinoma

## Interventions

- **DRUG:** Enituzumab injection+Abesili tablets+Anastrozole tablets

## Key facts

- **NCT ID:** NCT05167643
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-23
- **Primary completion:** 2022-10-23
- **Final completion:** 2024-08-23
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167643, "H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05167643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*